Hardy Chan – Chairman and President, Allianz Pharmascience, Taiwan

Dr Hardy Chan shares the story of how he came out of retirement to lead Allianz Pharmascience; an up-and-coming biotech which aims to meet the unmet medical needs of rare disease patients, particularly in Asia. Dr Chan delves deep into the innovative science behind the company’s pipeline and shares the patient-first commitment of the venture.  
I started Allianz as a personal dream to improve the lives of patients who would otherwise have virtually no hope
Become a PharmaBoardroom Member for free to access this content
Join the 20,000+ pharmaceutical professionals who already subscribe to PharmaBoardroom
Already a member? Sign In

Related Interviews

Latest Report